Impaired Tubular Uptake Explains Albuminuria in Early Diabetic Nephropathy

Leileata M. Russo,* Ruben M. Sandoval,† Silvia B. Campos,‡ Bruce A. Molitoris,†† Wayne D. Comper,§ and Dennis Brown*

*Program in Membrane Biology, Center for Systems Biology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts; †Department of Medicine, Division of Nephrology, Indiana Center for Biological Microscopy, Indiana University Medical Center, and ‡Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana; §Exosome Diagnostics Inc., New York, New York; and ††Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia

ABSTRACT

Understanding the pathogenesis of albuminuria in diabetic nephropathy is important to improve methods for early diagnosis and treatment. In this study, we addressed whether albuminuria in diabetes results from altered glomerular filtration and/or altered processing of filtered albumin by the proximal tubule. Type 1 diabetic Munich Wistar rats developed albuminuria after 12 wk of diabetes. Intravital two-photon microscopy revealed similar glomerular permeability in the diabetic and control animals, assessed using both albumin-Alexa568 and 69-kD FITC-dextran; however, diabetic animals demonstrated significantly less filtered fluorescent albumin in renal proximal tubule (PT) cells compared with control animals. We also observed increased albumin-derived urinary peptide excretion in diabetic animals, and hyperglycemia modulated this peptideuria. In conclusion, in the early stages of diabetic nephropathy, the PT plays a major role in the development of albuminuria, which may be preceded by peptideuria.


Received May 16, 2008. Accepted September 30, 2008.

Copyright © 2009 by the American Society of Nephrology

There has been much focus on the kidney filter as the primary factor for the manifestation of albuminuria in kidney disease, including diabetic nephropathy.1,2 Many studies have emphasized the importance of various structural elements of the glomerular capillary wall (GCW), including podocytes, in governing albuminuria in diabetes3,4; however, previous studies were unable to make direct measurements of GCW albumin permeability. There is now a debate as to whether the albuminuria that develops in diabetes and other renal diseases is of glomerular or PT origin.5

Here, we use intravital two-photon microscopy of infused albumin-Alexa568 and 69-kD FITC-dextran to examine directly and for the first time the in vivo processes of albumin filtration and proximal reabsorption in an animal model of diabetes.

We induced type 1 diabetes in rats using streptozotocin (STZ), a drug that targets and destroys β cells of the pancreas, producing a widely used and recognized model of insulin-dependent diabetes. Analysis of physiologic parameters after 12 wk of diabetes demonstrated significantly decreased body weight and increases in blood glucose, kidney weight, and osmotic diuresis accompanied by increased water intake, versus age-matched control rats (Supplemental Table 1). Analysis of urinary albumin excretion demonstrated significantly increased intact albumin excretion in the diabetic versus control groups (P < 0.05; Figure 1), consistent with the induction of diabetic nephropathy.

Intravital two-photon microscopy was used to determine the origin of the albuminuria. Anesthetized rats were administered an intravenous injection of rat serum albumin conjugated to Alexa568 (albumin-Alexa568; red).6 After the injection, fluorescent albumin was immediately filtered across glomerular capillaries, entered the urinary space, and avidly bound to the base of the PT cell brush border in both control and diabetic animals (Supplemental Movies 1 and 2, respectively). Superficial glomeruli and associated PTs were imaged for the first 3 min after albumin-Alexa568 injection, and short movies were also recorded at 12 and 24 min after injection for use in determining the albumin glomerular-sieving coefficient (GSC). We calculated GSC as the ratio of albumin-Alexa568 (or FITC-dextran in some experiments) in the glomerular filtrate.
merular capillary blood space versus that in the Bowman’s space at the interface with the S1 segment, after correction for background fluorescence (see the Concise Methods section). Results shown in Figure 2A reveal that the GSC of albumin in control rats was 0.0340 ± 0.0032 (n = 4), which is in agreement with the GSC that we previously reported for albumin using this method. Importantly, the albumin GSC in the diabetic rats was not significantly different from that in the control rats, with a value of 0.0290 ± 0.0047 (n = 4), despite the presence of albuminuria in the diabetic animals. To corroborate these data, we took a low polydisperse 69-kD FITC-dextran (which has a radius of 5.3 to 6.5 nm) and determined its sieving coefficient also over 24 min after injection using the same technique. In control rats (Figure 2B), FITC-dextran had a GSC of 0.0250 ± 0.0041 (n = 4); the diabetic rats had a similar GSC of 0.0240 ± 0.0021 (n = 5). This result is in agreement with the GSC measurement obtained for similar dextrans in an independent study in nondiabetic rats using a glomerular uptake technique, which reported a GSC of 0.022. This agreement between two different methods further substantiates the use of two-photon technology to quantify albumin GSC. All GSCs were time-independent throughout the 24-min period of measurement. These results reveal, therefore, that despite a doubling of intact albumin levels in the urine (Figure 1), there is no detectable

Figure 1. Intact urinary albumin excretion is increased in 12-wk diabetic rats. Urinary intact albumin excretion was measured by ELISA for rat serum albumin in 24-h urine samples of 12-wk diabetic rats and age-matched controls. Diabetic rats had significantly increased urinary intact albumin excretion (P < 0.05 control versus diabetic; control n = 4, diabetic n = 4).

Figure 2. The GSC of albumin and 69-kD FITC-dextran is unchanged in 12-wk diabetic versus control rats. (A) GSC of albumin-Alexa568 in 12-wk diabetic and aged-matched control rats demonstrates no significant change in the GSC for albumin (control n = 4, diabetic n = 4; 13 data points for control animals and 13 data points for diabetic animals over 24 min). (B) GSC of 69-kD FITC-dextran in 12-wk diabetic and aged-matched control rats demonstrates no significant change in the GSC for dextran, confirming the results obtained for albumin GSC (control n = 4, diabetic n = 5; 16 data points for control animals and 12 data points for diabetic animals taken over 24 min). (C) The plasma clearance of albumin-Alexa and 69-kD FITC-dextran over 24 h demonstrates that dextran is quickly cleared from the plasma over 24 h but a large portion of albumin is retained in the plasma despite the two molecules’ having similar GSC (albumin n = 4, dextran n = 4). (D) Representative pictures showing before and 24 min after injection of green 69-kD FITC-dextran (top) and red albumin-Alexa568 (bottom) in 12-wk control rats. Albumin (red) can be seen distributed in PT cells, whereas dextran (green) uptake is negligible. Bar = 30 μm. G, glomerulus; PT, proximal tubule.
change in glomerular permeability for albumin or for a 69-kD uncharged FITC-dextran at 12 wk after diabetes induction in this animal model, suggesting that the observed albuminuria has a nonglomerular origin.

Analysis of the proportion of albumin and dextran remaining in the plasma during 24 h in control rats (Figure 2C) revealed that only 0.92 ± 0.64% (n = 4) of the injected 69-kD FITC-dextran remained in the circulation after 24 h, whereas a much larger percentage of injected albumin-Alexa568 (37.6 ± 3.8%; n = 4) remained. Note that the serum concentration was also affected by redistribution into the extracellular volume space and other vascular compartments such as the lymph, in addition to elimination by the kidney. Given that these molecules have essentially the same GSCs, this strongly supports the theory that filtered albumin is rescued and returned to the circulation by the PT epithelium, as we proposed previously.6,9 This is further supported by the distribution of the albumin-Alexa and FITC-dextran in the S1 segment of the PT 24 min after injection, where albumin is seen distributed across PT cells of the S1 segment immediately leading from the Bowman’s capsule, whereas negligible dextran uptake is observed (Figure 2D). Previous evidence for the retrieval pathway is supported by (1) the use of toxins to inhibit tubular uptake, resulting in high levels of albumin in the urine10; (2) the recovery of filtered albumin in the peritubular capillary; and (3) the distribution of immunogold-labeled endogenous albumin in PT cells by electron microscopy and the distribution of exogenous fluorescence albumin in PT cells over time.6 It should be noted, however, that the exact nature of the cellular processes involved in the retrieval of glomerular filtered albumin still remains to be fully elucidated.

Analysis of albumin endocytosis and the distribution of albumin in the PT was carried out in 12-wk diabetic versus control rat kidneys at 2.5 and 24 min after albumin injection (Figure 3A). Albumin was localized mainly toward the apical pole in the diabetic animals compared with age-matched control animals (Figure 3B). The analysis of mean fluorescence intensity for fluorescently labeled albumin in S1 PT segments immediately adjoining the glomerulus revealed an approximate 45% reduction in the amount of albumin-associated fluorescence in the cells of diabetic versus control rat kidneys at 24 min after albumin-Alexa568 injection (Figure 3C; P < 0.01; n = 4 for each group). This suggests a significant change in PT handling of albumin in diabetes.

The amount of albumin handled by the renal PT given a GSC of 0.03 is in the vicinity of approximately 1 g/d per kidney in rats. This suggests that changes in the renal handling of albumin such as that demonstrated in Figure 3 should induce significant albuminuria; however, analysis of intact albumin in the urine revealed a relatively small two-fold increase to approximately 4 mg/d intact albumin in the diabetic group (Figure 1). Thus, we endeavored to determine whether there were any changes in total albumin excretion in the urine. Albumin in urine was previously shown to be present in two forms.11 The majority (approximately 150 mg/d in rats) is present as albumin-derived fragments...
and is “immuno-unreactive” in immuno-based assays that are used for the quantification of albuminuria. The second form of urinary albumin is intact albumin (approximately 1 mg/d in rats), which is “immuno-reactive.” The immuno-unreactive albumin-derived fragments from humans were characterized previously as having molecular weights in the range of 300 to 500 Da using radiolabeled albumin and the Biuret protein assay.12 Furthermore, peptide-derived fragments, which have molecular weights in the range of 300 to 500 Da, using radiolabeled albumin and the Biuret assay.13

In conclusion, these findings support an important paradigm shift in our understanding of the renal processing of albumin in diabetes and highlights the PT as an important element for albuminuria manifestation. The finding that considerable changes in the excretion of urinary albumin occurs during the very early stages of diabetic nephropathy, independent of glomerular permeability changes, offers important new insights into the development of new early diagnostics and treatments that may target the renal PT and glucose control.

**CONCISE METHODS**

**Animals**

All animal experiments were approved by the Institutional Committee on Research Animal Care, in accordance with the National Insti-
Physiologic Parameters

Intact albumin excretion was assayed using Nephrat competitive ELISA assay for rat serum albumin (Exocell, Philadelphia, PA). Total urinary protein was measured by total protein assay (micro-Lowry; Sigma-Aldrich). GFR was measured by creatinine assay as described previously. Blood glucose was measured by glucometer. BP was directly monitored via an arterial line connected to a Kent Scientific Corp. (Torrington, CT) pressure transducer and monitored using DASYLab software 6.0. In all subjects a broad pulsatile tracing was observed showing both systolic and diastolic pressures indicative of correct placement of the line within the arterial vasculature.

Albumin Fractional Clearance

Albumin fractional clearance was calculated as [urinary albumin/plasma albumin] × [urine flow rate/GFR]. Rat serum albumin (Sigma Chemical Co.) was carbon-14–labeled with 125 μCi [14C]formaldehyde (NEN Life Science Products, Boston, MA) using a modified reductive methylation technique. ALZET osmotic pumps, Model 2001 (Durect Corp., Cupertino, CA) were used to deliver [14C]albumin. For osmotic pump implantation, rats were anesthetized by Fortthane (Abbott Australasia Pty Ltd., Kurnell, Australia) inhalation, and an osmotic pump was implanted subcutaneously between the scapulae using sterile technique 1 wk before the end of the 12-wk study. At day 7 after osmotic pump implantation, rats were placed in metabolic cages for the collection of a 24-h urine sample. A corresponding blood sample was taken for the analysis of [14C]albumin fractional clearance.

Two-Photon Microscopy

All imaging was conducted using a Bio-Rad MRC-1024MP two-photon laser scanning microscope (Hercules, CA) mounted on a Nikon Diaphot inverted stage platform (Fryer, Huntley, IL) using a Ti:Sapphire laser (Spectra-Physics, Franklin, MA) as described previously. The microscope stage was warmed using a ReptiTherm heating pad (Zoo Med Laboratories, San Luis Obispo, CA) and animals were maintained at 37°C. Fluorescence probes were dissolved in isotonic saline and injected into the femoral vein of rats in a steady bolus of 0.1 to 0.4 ml over 5 s. In this study, nonsaturating levels of fluorescence were used. The magnification of the objective used was a ×60 water immersion lens with a 1.2 numerical aperture or a ×20 multi-immersion lens with a 0.75 numerical aperture. Images taken for quantification were obtained with the ×60 water immersion lens. Images were taken at a depth between 5 and 20 μm into the tissue. When free Alexa dye was injected into rats, it was rapidly filtered and concentrated in distal tubules. Importantly, it was not taken up by PTs (Supplemental Movie 3). This indicates that the presence of free dye and its association with other plasma proteins are not responsible for our observations. Furthermore, Alexa fluorescence in the plasma was associated only with a single band at the molecular weight of albumin, indicating that it does not associate with other proteins (Supplemental Figure 1).

Analysis of Albumin Uptake

Still frames from two-photon movies at 24 min taken with a ×60 water immersion lens with a 1.2 numerical aperture were captured and exported into IPLab spectrum. Four control kidneys and four diabetic kidneys were compared. An area of interest was drawn around the S1 PT and analyzed for mean pixel intensity. The mean area analyzed in both groups was not significantly different (control 162.6 ± 19.4 for diabetic 161.7 ± 15.4).

Proteins and Probes

Rat serum albumin (Fraction V; Sigma-Aldrich) was conjugated to Alexa568 (Molecular Probes, Carlsbad, CA) according to the manufacturer’s instructions for amine-reactive probes as previously reported. All samples were diazylated overnight to remove cacytodylate and free dye before injection into animals. FITC-dextran had a number average Mn of 45,500 Da, weight average molecular weight of 69,700, and average radius of 3.3 to 6.5 nm (gift from Pharmacia, Upplands, Sweden).
Statistical Analysis
Statistics were measured by a two-tailed t test. Data are means ± SEM unless noted otherwise.

ACKNOWLEDGMENTS
This work was supported by grants from the Juvenile Diabetes Research Foundation International (L.M.R. and W.D.C.). National Institutes of Health grant DK 061594 was awarded to B.A.M. to establish a George M. O’Brien Center for advanced renal microscopy analysis at the Indiana Centre for Biological Microscopy. The Microscopy Core Facility of the MGH Program in Membrane Biology receives support from National Institutes of Health grant DK58452 (D.B.), the Boston Area Diabetes and Endocrinology Research Center (DK57521), and the Center for the Study of Inflammatory Bowel Disease (DK43341). We thank Dr. Tanya Osicka and Steve Sastra for performing the fractional clearance studies.

This work was presented in part at the 68th scientific session of the American Diabetes Association; June 6 through 10, 2008; San Francisco, CA; and the 41st annual meeting of the American Society of Nephrology; November 4 through 9, 2008; Philadelphia, PA.

DISCLOSURES
None.

REFERENCES

Supplemental information for this article is available online at http://www.jasn.org/.